Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1063-1070.doi: 10.35541/cjd.20210324
• Original Articles • Previous Articles Next Articles
Song Xiaoting1, Liu Bo1, Chen Yudi2, Yu Miao1,3, Liao Shuanglu1, Luan Tingting1,3, Zhao Zuotao1
Received:
2021-04-21
Revised:
2021-09-21
Online:
2021-12-15
Published:
2021-12-01
Contact:
Zhao Zuotao
E-mail:zhaozuotaotao@163.com
Supported by:
Song Xiaoting, Liu Bo, Chen Yudi, Yu Miao, Liao Shuanglu, Luan Tingting, Zhao Zuotao. Efficacy and safety of omalizumab for treatment of chronic spontaneous urticaria[J]. Chinese Journal of Dermatology, 2021, 54(12): 1063-1070.doi:10.35541/cjd.20210324
[1] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[2] | 张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021,54(7):582⁃585. doi: 10.35541/cjd.20201261. |
[3] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1):1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
[4] | Konstantinou GN, Asero R, Maurer M, et al. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria[J]. Allergy, 2009,64(9):1256⁃1268. doi: 10.1111/j. 1398⁃9995.2009.02132.x. |
[5] | Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient⁃reported outcome instrument for assessing urticaria control[J]. J Allergy Clin Immunol, 2014,133(5):1365⁃1372,1372.e1⁃e6. doi: 10.1016/ j.jaci.2013.12.1076. |
[6] | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190. |
[7] | Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal important difference of the urticaria control test[J]. J Allergy Clin Immunol, 2017,140(6):1710⁃1713.e11. doi: 10. 1016/j.jaci.2017.04.050. |
[8] | Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)⁃⁃a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994,19(3):210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x. |
[9] | Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ′real⁃world′ evidence[J]. Expert Opin Biol Ther, 2018,18(4):425⁃448. doi: 10.1080/14712598.2018.1438406. |
[10] | Apalla Z, Sidiropoulos T, Kampouropoulou E, et al. Real⁃life, long⁃term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria[J]. Eur J Dermatol, 2020,30(6):716⁃722. doi: 10.1684/ejd.2020.3919. |
[11] | Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta⁃analysis of "real⁃world" evidence[J]. JAMA Dermatol, 2019,155(1):29⁃38. doi: 10.1001/jamadermatol.2018.3447. |
[12] | Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306. |
[13] | Curto⁃Barredo L, Spertino J, Figueras⁃Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria[J]. Br J Dermatol, 2018,179(1):210⁃212. doi: 10.1111/bjd.16379. |
[14] | Asero R, Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications[J]. Expert Rev Clin Immunol, 2021,17(3):247⁃254. doi: 10.1080/1744666X.2021.1882304. |
[15] | Fok JS, Kolkhir P, Church MK, et al. Predictors of treatment response in chronic spontaneous urticaria[J]. Allergy, 2021,76(10):2965⁃2981. doi: 10.1111/all.14757. |
[16] | Choi JH, Lee DH, Song WJ, et al. The KAAACI/KDA evidence⁃based practice guidelines for chronic spontaneous urticaria in Korean adults and children: part 2. Management of H1⁃antihistamine⁃refractory chronic urticaria[J]. Allergy Asthma Immunol Res, 2020,12(5):750⁃770. doi: 10.4168/aair.2020.12. 5.750. |
[17] | Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria[J]. Ann Allergy Asthma Immunol, 2015,115(2):126⁃129. doi: 10.1016/j.anai. 2015.05.010. |
[18] | Labrador⁃Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real⁃life practice[J]. Expert Opin Biol Ther, 2013,13(9):1225⁃1228. doi: 10.1517/14712598.2013.822484. |
[19] | Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab[J]. J Allergy Clin Immunol, 2008,122(3):569⁃573. doi: 10.1016/j.jaci.2008.07.006. |
[20] | Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab[J]. Acta Derm Venereol, 2010,90(4):443⁃444. doi: 10.2340/00015555⁃0884. |
[21] | Lefévre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria[J]. Ann Dermatol, 2013,25(2):242⁃245. doi: 10.5021/ad.2013.25.2.242. |
[22] | Kai AC, Flohr C, Grattan CE. Improvement in quality of life impairment followed by relapse with 6⁃monthly periodic administration of omalizumab for severe treatment⁃refractory chronic urticaria and urticarial vasculitis[J]. Clin Exp Dermatol, 2014,39(5):651⁃652. doi: 10.1111/ced.12320. |
[23] | Subramaniyan R, Chopra A. Treatment of chronic spontaneous urticaria with a single dose of omalizumab: a study of four cases[J]. Indian J Dermatol, 2016,61(4):467. doi: 10.4103/0019⁃5154.185745. |
[24] | Mandel VD, Guanti MB, Liberati S, et al. Omalizumab in chronic spontaneous urticaria refractory to conventional therapy: an italian retrospective clinical analysis with suggestions for long⁃term maintenance strategies[J]. Dermatol Ther (Heidelb), 2018,8(2):291⁃301. doi: 10.1007/s13555⁃018⁃0240⁃7. |
[25] | Maurer M, Kaplan A, Rosén K, et al. The XTEND⁃CIU study: long⁃term use of omalizumab in chronic idiopathic urticaria[J]. J Allergy Clin Immunol, 2018,141(3):1138⁃1139.e7. doi: 10. 1016/j.jaci.2017.10.018. |
[26] | Su O, Bahali AG, Onsun N. The effect of at least 1⁃year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria[J]. Dermatol Ther, 2020,33(6):e14192. doi: 10.1111/dth.14192. |
[27] | Acar A, Gerceker Turk B, Ertam Sagduyu I, et al. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience[J]. Cutan Ocul Toxicol, 2020,39(3):249⁃253. doi: 10.1080/15569527.2020.178 7432. |
[28] | Ocak M, Soyer O, Buyuktiryaki B, et al. Omalizumab treatment in adolescents with chronic spontaneous urticaria: efficacy and safety[J]. Allergol Immunopathol (Madr), 2020,48(4):368⁃373. doi: 10.1016/j.aller.2020.03.011. |
[29] | Papaianni V, Guarneri F, Vaccaro M, et al. From regulatory limitations to new opportunities: real⁃life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria[J]. Dermatol Ther, 2020,33(1):e13188. doi: 10.1111/dth.13188. |
[30] | Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: real life experience with twenty⁃five patients[J]. Allergol Int, 2018,67(1):85⁃89. doi: 10.1016/j.alit.2017.05.003. |
[31] | Sardana K, Dixit N, Arora P. A real⁃world analysis of relapse rate and efficacy of a restricted monthly dose of omalizumab in recalcitrant chronic spontaneous urticaria in India[J]. Indian Dermatol Online J, 2020,11(5):835⁃837. doi: 10.4103/idoj.IDOJ_499_19. |
[32] | Vadasz Z, Tal Y, Rotem M, et al. Omalizumab for severe chronic spontaneous urticaria: real⁃life experiences of 280 patients[J]. J Allergy Clin Immunol Pract, 2017,5(6):1743⁃1745. doi: 10. 1016/j.jaip.2017.08.035. |
[33] | Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(5):918⁃924. doi: 10.1111/jdv.15350. |
[34] | Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2017,140(6):1749⁃1751. doi: 10.1016/j.jaci.2017.08.007. |
[35] | Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022. |
[36] | Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria[J]. JAMA Dermatol, 2014,150(3):288⁃290. doi: 10.1001/jamadermatol.2013.8705. |
[37] | Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria[J]. J Allergy Clin Immunol Pract, 2019,7(5):1659⁃1661.e1. doi: 10.1016/j.jaip.2018.11.018. |
[38] | Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria[J]. Clin Exp Allergy, 2020,50(7):799⁃804. doi: 10. 1111/cea.13616. |
[39] | Sand FL, Thomsen SF. Off⁃label use of TNF⁃alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients[J]. Dermatol Ther, 2015,28(3):158⁃165. doi: 10.1111/dth.12222. |
[40] | Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa12 15372. |
[1] | Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263. |
[2] | Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218. |
[3] | Wang Juanjuan, Chen Rong, Ji Jiang, Su Wenxing, Wei Yuqian, Zhao Ying, Yin Xingping, Su Yuhua, Shi Xin. Retrospective analysis of 67 cases of neurosyphilis with abnormal mental behaviors as the initial symptom [J]. Chinese Journal of Dermatology, 2022, 55(3): 231-234. |
[4] | Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631. |
[5] | Wang Jiaqi, Wang Ping, Li Liuyu, Fan Qimin, Zhu Mengyan, Wang Yanqing, Zhou Hongyu, Shen Hong, Xu Ai′e. Cutaneous hypopigmented lymphoproliferative disorders: a clinicopathological study of 41 cases [J]. Chinese Journal of Dermatology, 2022, 55(2): 110-115. |
[6] | Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis [J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75. |
[7] | Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64. |
[8] | Guo Wei, Zhao Tao, Guo Weinan, Ma Cuiling, Gao Tianwen, Zhao Jianhong, Li Bing. Surgical treatment strategies and outcomes of early-stage nail apparatus melanoma: a retrospective analysis of 115 cases [J]. Chinese Journal of Dermatology, 2021, 54(9): 777-784. |
[9] | Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596. |
[10] | Zhang Yu, Gao Yingxia, Gu Ningyan, Zhu Hong, Chen Jingjing, Hu Qingjie, Zhou Min, Duan Yuanyuan, Yao Xu. Clinical efficacy and safety of omalizumab in the treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2021, 54(7): 582-585. |
[11] | Liang Gaopeng, Song Zhiqiang. Role of immunoglobulin E autoantibodies in autoimmune skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(6): 553-556. |
[12] | Li Yan, Xu Wei, Li Linfeng. Efficacy of topical hydrocortisone butyrate cream combined with a skin cream dressing in the treatment of atopic dermatitis: a randomized, open, controlled clinical study [J]. Chinese Journal of Dermatology, 2021, 54(5): 452-455. |
[13] | Hu Yanyan, Jiang Qian, Chen Liuqing, Li Dongsheng. Application of reflectance confocal microscopy in the evaluation of clinical efficacy of hemoporfin-mediated photodynamic therapy for purple-type port-wine stain [J]. Chinese Journal of Dermatology, 2021, 54(4): 342-346. |
[14] | Xie Bo, Wei Xiaodong, Xu Ai′e, Lin Fuquan, Zhou Miaoni. Efficacy of systemic glucocorticoid treatment and its related factors in patients with progressive vitiligo [J]. Chinese Journal of Dermatology, 2021, 54(2): 139-144. |
[15] | Yan Huimin, Du Xiao, Meng Linghe, Weng Lishuo, Zeng Sanwu. Analysis of differences in gut microbiota in patients with chronic spontaneous urticaria by 16S rRNA high-throughput sequencing [J]. Chinese Journal of Dermatology, 2021, 54(12): 1071-1076. |
|